Cardiovascular Diabetology (Jul 2021)

FGF21/adiponectin ratio predicts deterioration in glycemia: a 4.6-year prospective study in China

  • Dan Liu,
  • Liang Wu,
  • Qiongmei Gao,
  • Xiaoxue Long,
  • Xuhong Hou,
  • Lingling Qian,
  • Jiacheng Ni,
  • Qichen Fang,
  • Huating Li,
  • Weiping Jia

DOI
https://doi.org/10.1186/s12933-021-01351-1
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background The fibroblast growth factor (FGF) 21-adiponectin pathway is involved in the regulation of insulin resistance. However, the relationship between the FGF21-adiponectin pathway and type 2 diabetes in humans is unclear. Here, we investigated the association of FGF21/adiponectin ratio with deterioration in glycemia in a prospective cohort study. Methods We studied 6361 subjects recruited from the prospective Shanghai Nicheng Cohort Study in China. The association between baseline FGF21/adiponectin ratio and new-onset diabetes and incident prediabetes was evaluated using multiple logistic regression analysis. Results At baseline, FGF21/adiponectin ratio levels increased progressively with the deterioration in glycemic control from normal glucose tolerance to prediabetes and diabetes (p for trend 0.05). Furthermore, net reclassification improvement and integrated discrimination improvement analyses showed that FGF21/adiponectin ratio provided a better performance in diabetes risk prediction than the use of FGF21 or adiponectin alone. Conclusions FGF21/adiponectin ratio independently predicted the onset of prediabetes and diabetes, with the potential to be a useful biomarker of deterioration in glycemia.

Keywords